Figure 5. Combination of rhTRAIL and ONC201 in the MDA-MB-361 xenograft model.

(A) Growth rates were calculated for MDA-MB-361 xenograft tumors were treated weekly with a vehicle control, 100 mg/kg ONC201 orally, 10 mg/kg rhTRAIL intravenously, or a combination of ONC201 and rhTRAIL. rhTRAIL was given 72 hours after ONC201. Mice were treated for a total of three cycles. (B) Mice bearing MDA-MB-361 xenograft tumors were treated weekly with a vehicle control, 100 mg/kg ONC201 orally, 5 mg/kg rhTRAIL intravenously, or a combination of ONC201 and rhTRAIL. rhTRAIL was given 72 hours after ONC201. Mice were treated for a total of three cycles. (C) Data sets in A and B were combined and re-analyzed. Tumor volumes were measured as (w² × l)/2 where w is tumor width and l is tumor length. 5–7 tumors were included per group.